Literature DB >> 12490608

Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist.

Philip Hasbak1, Ole Saetrum Opgaard, Karen Eskesen, Søren Schifter, Henrik Arendrup, Jenny Longmore, Lars Edvinsson.   

Abstract

Calcitonin gene-related peptide (CGRP), adrenomedullin (AM), and amylin are structurally related peptides mediating vasorelaxation in the coronary circulation possibly via CGRP receptors (subtypes 1 or 2). Functional CGRP1 receptors appear to consist of at least three different kinds of proteins: the calcitonin receptor-like receptor (CRLR), receptor-activity-modifying proteins (RAMPs) and the receptor component protein (RCP). No CGRP2 receptor has yet been cloned. Using reverse transcriptase - polymerase chain reaction, the presence of mRNA sequences encoding CRLR, RCP and RAMPs was demonstrated in human coronary arteries. Relaxant responses were studied on isolated segments of coronary arteries after precontraction with U46619 (9,11-dideoxy-11alpha,9alpha-epoxymethano-prostaglandin F(2alpha)). The human peptides alphaCGRP, AM, and amylin induced relaxation with mean pEC50 values of 8.6, 6.8, and 6.3 M, respectively. Preincubation with alphaCGRP(8-37) (10(-7) -10(-5) M) and a novel nonpeptide CGRP antagonist "Compound 1" (WO98/11128) (10(-7)-10(-5) M) caused a dose-dependent rightward shift of the concentration-response curves for alphaCGRP with pA(2) values of 7.0 and 7.1, respectively. Preincubation with alphaCGRP(8-37) (10(-6) M) and Compound 1 (10(-6) M) caused significant rightward shift of the concentration-response curves for AM and amylin as well with pK B values between 6.6 and 7.5. Preincubation with AM(22-52) had no antagonistic effect on the AM and amylin response, neither did diacetoamidomethyl cysteine CGRP cause any concentration dependent (10(-11)-10(-6) M) dilatation. In conclusion, mRNA for the components forming CGRP1 and AM receptors was detected in the human left anterior descending coronary arteries. alphaCGRP, AM, and amylin mediated vasorelaxation via the CGRP1 receptor. Compound 1 acted as a nonpeptide antagonist at the CGRP1 receptor and could thus become a tool for the study of CGRP-mediated functional responses in human tissue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12490608     DOI: 10.1124/jpet.102.037754

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Increased alphaCGRP potency and CGRP-receptor antagonist affinity in isolated hypoxic porcine intramyocardial arteries.

Authors:  Philip Hasbak; Karen Eskesen; Søren Schifter; Lars Edvinsson
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

2.  Calcitonin gene-related peptide contributes to the umbilical haemodynamic defence response to acute hypoxaemia.

Authors:  A S Thakor; D A Giussani
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

3.  Direct interactions between calcitonin-like receptor (CLR) and CGRP-receptor component protein (RCP) regulate CGRP receptor signaling.

Authors:  Sophie C Egea; Ian M Dickerson
Journal:  Endocrinology       Date:  2012-02-07       Impact factor: 4.736

Review 4.  CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

Authors:  C S Walker; D L Hay
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.

Authors:  David Bell; Malcolm Campbell; Matthew Ferguson; Leah Sayers; Liz Donaghy; Anna O'Regan; Victoria Jewhurst; Mark Harbinson
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

6.  Calcitonin gene-related peptide antagonism attenuates the haemodynamic and glycaemic responses to acute hypoxaemia in the late gestation sheep fetus.

Authors:  A S Thakor; M R Bloomfield; M Patterson; D A Giussani
Journal:  J Physiol       Date:  2005-04-28       Impact factor: 5.182

Review 7.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

8.  CGRP receptor antagonists: A new frontier of anti-migraine medications.

Authors:  Blanca Marquez de Prado; Andrew F Russo
Journal:  Drug Discov Today Ther Strateg       Date:  2006

9.  Noncompetitive antagonism of BIBN4096BS on CGRP-induced responses in human subcutaneous arteries.

Authors:  Majid Sheykhzade; Henrik Lind; Lars Edvinsson
Journal:  Br J Pharmacol       Date:  2004-10-11       Impact factor: 8.739

Review 10.  Calcitonin gene-related peptide: physiology and pathophysiology.

Authors:  F A Russell; R King; S-J Smillie; X Kodji; S D Brain
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.